 | • レポートコード：D0-MOR-AP0686 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、インクレチンベース薬の世界市場について調査・分析した資料で、インクレチンベース薬の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The Incretin-Based Drugs market studied is anticipated to grow with a CAGR of nearly 5.2%, during the forecast period.
· Certain factors that are driving the market growth include rising prevalence of obsesity and diabetes and growing awareness and R&D activities.
· There has been a tremendous increase in the diabetic population, across the globe, over the past decade. Several reports and surveys documented drastic increase in the diabetic population, based on the changing life style and habits. For instance, according to the British Diabetic Association, it is estimated that almost 3.7 million people are living with diabetes in the United Kingdom and the number has doubled in the past two decades. Moreover, around 12.3 million people are at an increased risk of Type 2 diabetes in the United Kingdom, and obesity is the leading cause in the majority of preventable cases.
· The two most recently approved classes of therapeutic agents for the treatment of type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists and dipeptidyl peptidase-4 inhibitors (DPP-4i), exert their actions through potentiation of incretin receptor signaling. Incretins are gut-derived hormones, principally GLP-1 and glucose-dependent insulinotropic peptide (GIP), that are secreted at low basal levels in the fasting state. The ongoing research and development activities on these incretin-based drugs are expected to drive the market growth over the forecast period.
Key Market Trends
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Holds Significant Share in the Global Incretin-Based Drugs Market
The incretin system has become an important target in the treatment of type 2 diabetes and the most recent understanding of this deficit suggests that it relates to deterioration of the GLP-1 effect, with impaired capacity to secrete insulin, increasing insulin resistance, and hyperglycemia, perhaps leading to a decrease in GLP-1 receptor expression and resulting in GLP-1 resistance.
Hence, in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists.
The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide.
North America Dominates the Global Incretin-Based Drugs Market
Over the past decade, the prevalence of diabetes in North America has increased. People with diabetes need proper and effective therapeutics, and hence the demand for incretin-based drugs is observing a significant rise all across the region.
In Canada, the prevalence of diabetes among adults is 10.2% and about 3.6 million patients were suffering from diabetes in 2017. The number of patients suffering from type 2 diabetes is 94.4% of the diabetic population.
Furthermore, the prevalence of diabetes is rising among all age groups, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people.
Competitive Landscape
The global Incretin-Based Drugs market is competitive and consists of a few major players. Companies like AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly, GlaxoSmithKline Plc., Merck Sharp & Dohme Corp, Novartis AG, Novo Nordisk, Sanofi, among others, hold the substantial market share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Obsesity and Diabetes
4.2.2 Growing Awareness and R&D Activities
4.3 Market Restraints
4.3.1 Lack of Reimbursement
4.3.2 Poor Accessibility to Drugs Especially in Developing Countries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
5.1.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Boehringer Ingelheim Pharmaceuticals, Inc.
6.1.3 Eli Lilly
6.1.4 GlaxoSmithKline Plc.
6.1.5 Merck Sharp & Dohme Corp
6.1.6 Novartis AG
6.1.7 Novo Nordisk
6.1.8 Sanofi
7 MARKET OPPORTUNITIES AND FUTURE TRENDS